Home > Boards > US Listed > Biotechs > Vascular Biogenics Ltd. (VBLT)

SNO conference next week. Supposed to present

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
MF82 Member Profile
 
Followed By 5
Posts 303
Boards Moderated 0
Alias Born 06/01/14
160x600 placeholder
Vascular Biogenics Ltd. Closes Public Offering of Ordinary Shares and Pre-Funded Warrants GlobeNewswire Inc. - 4/14/2021 6:00:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 4/12/2021 9:11:07 AM
Vascular Biogenics prices $25M stock offering Seeking Alpha - 4/9/2021 9:06:18 AM
Vascular Biogenics Ltd. Prices Public Offering of Ordinary Shares and Pre-Funded Warrants GlobeNewswire Inc. - 4/9/2021 8:58:12 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 4/9/2021 6:01:40 AM
Vascular Biogenics proposes capital raise Seeking Alpha - 4/8/2021 4:44:26 PM
Vascular Biogenics Ltd. Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants GlobeNewswire Inc. - 4/8/2021 4:05:00 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 4/6/2021 3:34:17 PM
VBL Therapeutics to Host Virtual R&D Day on April 6 GlobeNewswire Inc. - 3/30/2021 7:00:00 AM
VBL Therapeutics EPS misses by $0.02, misses on revenue Seeking Alpha - 3/25/2021 7:10:38 AM
Annual and Transition Report (foreign Private Issuer) (20-f) Edgar (US Regulatory) - 3/25/2021 7:01:50 AM
VBL Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update GlobeNewswire Inc. - 3/25/2021 7:00:00 AM
VBL Therapeutics to Report Fourth Quarter and Full Year Financial Results on March 25 GlobeNewswire Inc. - 3/17/2021 7:00:00 AM
VBL Therapeutics to Participate at Upcoming Virtual Investor Conferences GlobeNewswire Inc. - 3/8/2021 7:00:00 AM
VBL Therapeutics' stock up on late-stage VB-111 ovarian cancer study results Seeking Alpha - 3/4/2021 8:33:16 AM
VBL Therapeutics Announces Peer-reviewed Publication of Positive Results of Pre-specified Interim Analysis of OVAL, a Phase 3... GlobeNewswire Inc. - 3/4/2021 7:00:00 AM
VBL Therapeutics Announces Patient Dosing Initiated in Randomized, Controlled and Blinded Trial of VB-111 in Patients with Re... GlobeNewswire Inc. - 3/1/2021 7:00:00 AM
VET, TCOM, TTM and ZI among premarket gainers Seeking Alpha - 2/23/2021 8:18:53 AM
VBL Therapeutics gets green light for VB-111 study in ovarian cancer, shares up 16% Seeking Alpha - 2/22/2021 7:32:38 AM
VBL Therapeutics Announces Data Safety Monitoring Committee Provides Green Light to Advance the OVAL Phase 3 Registration Ena... GlobeNewswire Inc. - 2/22/2021 7:00:00 AM
VBL Therapeutics Treats First Patient in Phase 2 Randomized Controlled Study of VB-201 in COVID-19 Patients GlobeNewswire Inc. - 1/27/2021 7:00:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 1/15/2021 7:05:09 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 1/15/2021 7:03:58 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 1/11/2021 6:02:46 AM
Securities Registration (foreign Private Issuer) (f-3) Edgar (US Regulatory) - 12/30/2020 4:17:39 PM
MF82   Wednesday, 11/07/18 04:21:42 PM
Re: None
Post # of 2015 
SNO conference next week. Supposed to present findings from phase 3 rgbm vb111 failure...according to Q2 earnings call...

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences